# A Trial of Vigil for Participants With Ovarian Cancer

Source: https://onco.cc/trials/nct02346747/  
OnCo record `nct02346747` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Vigil in ovarian cancer, run by Gradalis, Inc., active and no longer recruiting.

## Summary

A Trial of Vigil for Participants With Ovarian Cancer is a phase 2 interventional study registered as NCT02346747 by Gradalis, Inc., with 92 participants enrolled, started 2015-02 and due to reach its primary completion in 2028-12. Interventions recorded: Vigil.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02346747
- Phase: 2
- Setting: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
- Sponsor: Gradalis, Inc.
- Enrolled: 92

## Sources

- ClinicalTrials.gov NCT02346747: https://clinicaltrials.gov/study/NCT02346747

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/nct02346747.json